ClinicalTrials.gg
CompletedNCT03036488Updated Oct 22, 2026Results posted

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

A Phase 3 interventional study of Pembrolizumab and Carboplatin in Triple Negative Breast Neoplasms, sponsored by Merck Sharp & Dohme LLC. Completed at 193 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

How we know · 16 judgments

Updated Oct 22, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,174
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies testing pembrolizumab in Triple Negative Breast Neoplasms — 17 open to participants now, 27 under way, 4 of them phase 3. pembrolizumab · Triple Negative Breast Neoplasms.

Enrollment
4th of 49
1,174 · median 52
Started
2017
with 8 others
Phase 3
7 of 49
3 open now
Registered
15th of 49
by date
Lead sponsor
5 of 49
Merck Sharp & Dohme LLC

Among the 49 studies testing pembrolizumab in Triple Negative Breast Neoplasms, this one is the 4th largest by enrollment, is one of 9 that started in 2017, is one of 7 in phase 3, and was the 15th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

17 of the 49 studies testing pembrolizumab in Triple Negative Breast Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing pembrolizumab in Triple Negative Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475) plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy and pembrolizumab vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC).

After a screening phase of approximately 28 days, each participant will receive neoadjuvant study treatment (Pembrolizumab + Chemotherapy OR Placebo + Chemotherapy) based on the randomization schedule for approximately 24 weeks (8 cycles). Each participant will then undergo definitive surgery 3-6 weeks after conclusion of the last cycle of the neoadjuvant study treatment. After definitive surgery, each participant will receive adjuvant study treatment (Pembrolizumab OR Placebo) for approximately 27 weeks (9 cycles). Following adjuvant study treatment, each participant will be monitored for safety, survival and disease recurrence.

The primary study hypothesis is that pembrolizumab is superior to placebo, in combination with chemotherapy, as measured by the rate of Pathological Complete Response (pCR) and/or Event-free Survival (EFS), in participants with locally advanced TNBC.

03

Conditions studied

  • Triple Negative Breast Neoplasms

Keywords

  • PD1
  • PD-1
  • PDL1
  • PD-L1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has newly diagnosed, locally advanced, centrally confirmed TNBC, as defined by the most recent American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines.
  • Has previously untreated locally advanced non- (M0) TNBC defined as the following combined primary tumor (T) and regional lymph node (N) staging per current American Joint Committee of Cancer (AJCC) staging criteria for breast cancer as assessed by the investigator based on radiological and/or clinical assessment:

    • T1c, N1-N2
    • T2, N0-N2
    • T3, N0-N2
    • T4a-d, N0-N2
  • Provides a core needle consisting of at least 2 separate tumor cores from the primary tumor at screening to the central laboratory.
  • Has (ECOG) performance status of 0 or 1 performed within 10 days of treatment initiation.
  • Demonstrates adequate organ function.
  • Males and female participants of must be willing to use an adequate method of for the course of the study through 12 months after the last dose of study treatment for participants who have received cyclophosphamide, and 6 months after the last dose of study treatment for participants who did not.

Exclusion criteria

Exclusion Criteria:

  • Has a history of invasive ≤5 years prior to signing except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
  • Has received prior chemotherapy, targeted therapy, and radiation therapy within the past 12 months.
  • Has received prior therapy with an anti-programmed cell death protein 1 (), anti-programmed death - ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated antigen-4 [CTLA-4], OX-40, CD137 [tumor necrosis factor receptor superfamily member 9 (TNFRSF9)]) or has previously participated in a pembrolizumab (MK-3475) clinical study.
  • Is currently participating in or has participated in an interventional clinical study with an compound or device within 4 weeks of the first dose of treatment in this current study.
  • Has received a within 30 days of the first dose of study treatment.
  • Has an active disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, or drugs).
  • Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (i.e., dosing exceeding 10 mg daily of prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.
  • Has a known history of (HIV).
  • Has known active or .
  • Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.
  • Has an active infection requiring systemic therapy.
  • Has significant cardiovascular disease, such as: history of myocardial infarction, acute coronary syndrome or coronary angioplasty/stenting/bypass grafting within the last 6 months OR congestive heart failure (CHF) (NYHA) Class II-IV or history of CHF NYHA Class III or IV.
  • Is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the study, starting with the screening visit through 12 months after the last dose of study treatment for participants who have received cyclophosphamide, and for 6 months after the last dose of study treatment for participants who have not.
  • Has a known to the components of the study treatment or its analogs.
  • Has a known history of active tuberculosis (TB, Bacillus Tuberculosis).
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,174 participants (actual)

Study arms

  • Experimental
    Pembrolizumab + Chemotherapy

    Participants receive 200 mg pembrolizumab every 3 weeks (Q3W) + 80 mg/m\^2 paclitaxel weekly + carboplatin (Area Under the Curve \[AUC\]1.5 weekly or AUC5 Q3W) x 4 cycles, followed by 200 mg pembrolizumab Q3W + (60 mg/m\^2 doxorubicin OR 90 mg/m\^2 epirubicin) + 600 mg/m\^2 cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by 9 cycles of 200 mg pembrolizumab Q3W as adjuvant therapy post-surgery. Each cycle is 21 days.

    Biological: Pembrolizumab · Drug: Carboplatin · Drug: Paclitaxel · Drug: Doxorubicin · Drug: Epirubicin · Drug: Cyclophosphamide · Biological: Granulocyte colony stimulating factor: Filgrastim or Pegfilgrastim

  • Active comparator
    Placebo + Chemotherapy

    Participants receive placebo (normal saline solution) Q3W + 80 mg/m\^2 paclitaxel weekly + carboplatin (AUC1.5 weekly or AUC5 Q3W) x 4 cycles, followed by placebo + (60 mg/m\^2 doxorubicin OR 90 mg/m\^2 epirubicin) + 600 mg/m\^2 cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by 9 cycles of placebo Q3W as adjuvant therapy post-surgery. Each cycle is 21 days.

    Drug: Carboplatin · Drug: Paclitaxel · Drug: Doxorubicin · Drug: Epirubicin · Drug: Cyclophosphamide · Drug: Placebo · Biological: Granulocyte colony stimulating factor: Filgrastim or Pegfilgrastim

Interventions

  • BiologicalPembrolizumab

    On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; intravenous (IV) infusion.

    Also known as: MK-3475, KEYTRUDA®

  • On Day 1 of Cycles 1-4 of the neoadjuvant phase of the study OR on Days 1, 8, 15 of Cycles 1-4 of the neoadjuvant phase of the study; IV infusion.

    Also known as: PARAPLATIN®

  • On Days 1, 8 and 15 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion.

    Also known as: TAXOL®

  • On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.

    Also known as: ADRIAMYCIN®

  • On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.

    Also known as: ELLENCE®

  • On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion.

    Also known as: CYTOXAN®

  • DrugPlacebo

    normal saline solution or dextrose: On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; IV infusion

  • BiologicalGranulocyte Colony-Stimulating FactorStudies of Granulocyte Colony-Stimulating FactorGranulocyte Colony-Stimulating Factor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    For prevention of neutropenia, filgrastim 5 μg/kg/day via subcutaneous (SC) injection administered per standard of care after chemotherapy OR pegfilgrastim 100 µg/kg (individualized) or 6 mg (general approach) via SC injection administered per standard of care.

    Also known as: NEUPOGEN®, NEULASTA®

06

What researchers measure

Primary outcomes

  1. Pathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0 (i.e., no Invasive Residual in Breast or Nodes; Noninvasive Breast Residuals Allowed) as Assessed at the Time of Definitive Surgery in All Participants

    pCR rate (ypT0/Tis ypN0) was defined as the percentage of participants without residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy by current American Joint Committee on Cancer (AJCC) staging criteria assessed by the local pathologist at the time of definitive surgery.

    Time frame: Up to approximately 27-30 weeks

  2. Event-free Survival (EFS) in All Participants

    EFS was defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes definitive surgery, local or distant recurrence, second primary malignancy, as assessed by Investigator, or death due to any cause.

    Time frame: Up to approximately 102 months

Secondary outcomes

  1. Overall Survival (OS) in All Participants

    OS was defined as the time from randomization to death due to any cause.

    Time frame: Up to approximately 102 months

  2. pCR Rate Using an Alternative Definition, ypT0 ypN0 (i.e., no Invasive or Noninvasive Residual in Breast or Nodes) at the Time of Definitive Surgery in All Participants

    pCR rate (ypT0 ypN0) was defined as the percentage of participants without residual invasive and in situ cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy by current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery.

    Time frame: Up to approximately 27-30 weeks

  3. pCR Rate Using an Alternative Definition, ypT0 ypN0 (i.e., no Invasive or Noninvasive Residual in Breast or Nodes) at the Time of Definitive Surgery in Participants With Programmed Death Ligand 1 (PD-L1) Positive Tumors (Combined Positive Score [CPS] ≥ 1)

    pCR rate (ypT0 ypN0) was defined as the percentage of participants without residual invasive and in situ cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy by current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery.

    Time frame: Up to approximately 27-30 weeks

  4. pCR Rate Using the Definition of ypT0/Tis ypN0 (i.e., no Invasive Residual in Breast or Nodes; Noninvasive Breast Residuals Allowed) at the Time of Definitive Surgery in Participants With PD-L1 Positive Tumors (CPS ≥ 1)

    pCR rate (ypT0/Tis ypN0) was defined as the percentage of participants without residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy by current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery.

    Time frame: Up to approximately 27-30 weeks

  5. EFS in Participants With PD-L1 Positive Tumors (CPS ≥ 1)

    EFS was defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes definitive surgery, local or distant recurrence, second primary malignancy, as assessed by Investigator, or death due to any cause.

    Time frame: Up to approximately 102 months

  6. pCR Rate Using an Alternative Definition, ypT0/Tis (i.e., Absence of Invasive Cancer in the Breast Irrespective of Ductal Carcinoma in Situ or Nodal Involvement) at the Time of Definitive Surgery in All Participants

    pCR rate (ypT0/Tis) was defined as the percentage of participants without invasive cancer in the breast irrespective of ductal carcinoma in situ or nodal involvement following completion of neoadjuvant systemic therapy by current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery.

    Time frame: Up to approximately 27-30 weeks

  7. pCR Rate Using an Alternative Definition, ypT0/Tis (i.e., Absence of Invasive Cancer in the Breast Irrespective of Ductal Carcinoma in Situ or Nodal Involvement) at the Time of Definitive Surgery in Participants With PD-L1 Positive Tumors (CPS ≥ 1)

    pCR rate (ypT0/Tis) was defined as the percentage of participants without invasive cancer in the breast irrespective of ductal carcinoma in situ or nodal involvement following completion of neoadjuvant systemic therapy by current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery.

    Time frame: Up to approximately 27-30 weeks

  8. Overall Survival (OS) in Participants With PD-L1 Positive Tumors (CPS ≥ 1)

    OS was defined as the time from randomization to death due to any cause.

    Time frame: Up to approximately 102 months

  9. Number of Participants Who Experienced an Adverse Event (AE)

    An AE was any untoward medical occurrence in a participant administered a pharmaceutical product which does not have to have a causal relationship with this treatment. An AE can be any unfavorable and unintended sign (including abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the product or procedure. Any worsening (any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the Sponsor's product was an AE. The number of participants who experienced an AE was reported. AEs were reported for the neoadjuvant phase, adjuvant phase, and combined phases. Each participant is counted a single time for each applicable adverse event per treatment phase (i.e. Neoadjuvant, Adjuvant, Combined).

    Time frame: Up to approximately 107 weeks

  10. Number of Participants Who Discontinued Study Treatment Due to an AE

    An AE was any untoward medical occurrence in a participant administered a pharmaceutical product which does not have to have a causal relationship with this treatment. An AE can be any unfavorable and unintended sign (including abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the product or procedure. Any worsening (clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the Sponsor's product was an AE. The number of participants who discontinued study treatment due to an AE was reported for the neoadjuvant phase, adjuvant phase, and combined phases. Each participant is counted a single time for each applicable event per treatment phase (i.e. Neoadjuvant, Adjuvant, Combined).

    Time frame: Up to approximately 95 weeks

  11. Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score in All Participants

    The EORTC QLQ-C30 assesses quality of life in cancer patients and includes 30 questions: 1 global scale; 5 functional scales (physical, role, cognitive, emotional, social); 3 symptom scales (fatigue, nausea, pain); 6 symptoms (dyspnea, appetite loss, insomnia, constipation, diarrhea); \& financial impact. Items are scored on a 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scale scores are standardized to 0-100. Higher global and functional scores indicate better functioning, while higher symptom scores indicate worse symptoms. Results were presented separately for the neoadjuvant and adjuvant phases, with side-by-side review of phase-specific outputs. A combined phase analysis was not presented because the phases represent distinct clinical settings with different baselines; the adjuvant population is a subset of the neoadjuvant population; and pooling data would introduce substantial missingness, limiting clinical interpretability of the results.

    Time frame: Neoadjuvant: Baseline and Week 21; Adjuvant: Baseline and Week 24

  12. Change From Baseline in EORTC QLQ-C30 Score in Participants With PD-L1 Positive Tumors (CPS ≥ 1)

    The EORTC QLQ-C30 assesses quality of life in cancer patients and includes 30 questions: 1 global scale; 5 functional scales (physical, role, cognitive, emotional, social); 3 symptom scales (fatigue, nausea, pain); 6 symptoms (dyspnea, appetite loss, insomnia, constipation, diarrhea); \& financial impact. Items are scored on a 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scale scores are standardized to 0-100. Higher global and functional scores indicate better functioning, while higher symptom scores indicate worse symptoms. Results were presented separately for the neoadjuvant and adjuvant phases, with side-by-side review of phase-specific outputs. A combined phase analysis was not presented because the phases represent distinct clinical settings with different baselines; the adjuvant population is a subset of the neoadjuvant population; and pooling data would introduce substantial missingness, limiting clinical interpretability of the results.

    Time frame: Neoadjuvant: Baseline and Week 21; Adjuvant: Baseline and Week 24

  13. Change From Baseline in EORTC Breast Cancer-Specific Quality of Life Questionnaire (QLQ-BR23) Breast Symptoms Score in All Participants

    The EORTC QLQ-BR23 is a breast-specific module of the EORTC QLQ. It includes 23 items composed of 4 functional scales (body image, sexual functioning, sexual enjoyment, future perspective) and 4 symptom scales (systemic therapy side effects, breast symptoms, arm symptoms and upset by hair loss). Individual responses are given on a 4-point scale (1=Not at All to 4=Very Much). Scores for each scale are standardized into a range of 0 to 100. A higher score on the symptom scale shows a higher ("worse") level of symptoms. Results were presented separately for the neoadjuvant and adjuvant phases, with side-by-side review of phase-specific outputs. A combined phase analysis was not presented because the phases represent distinct clinical settings with different baselines; the adjuvant population is a subset of the neoadjuvant population; and pooling data would introduce substantial missingness, limiting clinical interpretability of the results.

    Time frame: Neoadjuvant: Baseline and Week 21; Adjuvant: Baseline and Week 24

  14. Change From Baseline in EORTC QLQ-BR23 Breast Symptoms Score in Participants With PD-L1 Positive Tumors (CPS ≥ 1)

    The EORTC QLQ-BR23 is a breast-specific module of the EORTC QLQ. It includes 23 items composed of 4 functional scales (body image, sexual functioning, sexual enjoyment, future perspective) and 4 symptom scales (systemic therapy side effects, breast symptoms, arm symptoms and upset by hair loss). Individual responses are given on a 4-point scale (1=Not at All to 4=Very Much). Scores for each scale are standardized into a range of 0 to 100. A higher score on the symptom scale shows a higher ("worse") level of symptoms. Results were presented separately for the neoadjuvant and adjuvant phases, with side-by-side review of phase-specific outputs. A combined phase analysis was not presented because the phases represent distinct clinical settings with different baselines; the adjuvant population is a subset of the neoadjuvant population; and pooling data would introduce substantial missingness, limiting clinical interpretability of the results.

    Time frame: Neoadjuvant: Baseline and Week 21; Adjuvant: Baseline and Week 24

07

Results

Posted Oct 22, 2026

Participant flow

Participant flow — Overall Study
MilestonePembrolizumab + ChemotherapyPlacebo + Chemotherapy
Started784390
Treated in the neoadjuvant phase783389
Received surgery768381
Treated in the adjuvant phase588331
Completed00
Not completed784390
Withdrew: Withdrawal by subject128
Withdrew: Sponsor decision652295
Withdrew: Lost to follow-up10
Withdrew: Death11987

Outcome measures

SecondaryOverall Survival (OS) in All Participants

OS was defined as the time from randomization to death due to any cause.

Time frame:
Up to approximately 102 months
Reported as:
Median · Months
Overall Survival (OS) in All Participants
MonthsPembrolizumab + ChemotherapyPlacebo + Chemotherapy
Overall Survival (OS) in All ParticipantsNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy · Log Rank · p = .0007538 (One-sided p-value based on log-rank test stratified by nodal status (positive vs. negative), tumor size (T1/T2 vs. T3/T4) and choice of carboplatin (Q3W vs. Weekly).) · Hazard ratio (hr): 0.64 · 95% CI 0.49 to 0.85Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by nodal status (positive vs. negative), tumor size (T1/T2 vs. T3/T4) and choice of carboplatin (Q3W vs. Weekly).
SecondarypCR Rate Using an Alternative Definition, ypT0 ypN0 (i.e., no Invasive or Noninvasive Residual in Breast or Nodes) at the Time of Definitive Surgery in All Participants

pCR rate (ypT0 ypN0) was defined as the percentage of participants without residual invasive and in situ cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy by current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery.

Time frame:
Up to approximately 27-30 weeks
Reported as:
Number · Percentage of Participants
pCR Rate Using an Alternative Definition, ypT0 ypN0 (i.e., no Invasive or Noninvasive Residual in Breast or Nodes) at the Time of Definitive Surgery in All Participants
Percentage of ParticipantsPembrolizumab + ChemotherapyPlacebo + Chemotherapy
pCR Rate Using an Alternative Definition, ypT0 ypN0 (i.e., no Invasive or Noninvasive Residual in Breast or Nodes) at the Time of Definitive Surgery in All Participants58.7 (54.9 to 62.5)49.5 (44.1 to 55.1)
Statistical analysis
  • Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy · Difference in percentage: 9.1 · 95% CI 2.6 to 15.5Based on Miettinen \& Nurminen method stratified by nodal status (positive vs. negative), tumor size (T1/T2 vs. T3/T4) and choice of carboplatin (Q3W vs. Weekly).
SecondarypCR Rate Using an Alternative Definition, ypT0 ypN0 (i.e., no Invasive or Noninvasive Residual in Breast or Nodes) at the Time of Definitive Surgery in Participants With Programmed Death Ligand 1 (PD-L1) Positive Tumors (Combined Positive Score [CPS] ≥ 1)

pCR rate (ypT0 ypN0) was defined as the percentage of participants without residual invasive and in situ cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy by current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery.

Time frame:
Up to approximately 27-30 weeks
Reported as:
Number · Percentage of Participants
pCR Rate Using an Alternative Definition, ypT0 ypN0 (i.e., no Invasive or Noninvasive Residual in Breast or Nodes) at the Time of Definitive Surgery in Participants With Programmed Death Ligand 1 (PD-L1) Positive Tumors (Combined Positive Score [CPS] ≥ 1)
Percentage of ParticipantsPembrolizumab + ChemotherapyPlacebo + Chemotherapy
pCR Rate Using an Alternative Definition, ypT0 ypN0 (i.e., no Invasive or Noninvasive Residual in Breast or Nodes) at the Time of Definitive Surgery in Participants With Programmed Death Ligand 1 (PD-L1) Positive Tumors (Combined Positive Score [CPS] ≥ 1)62.0 (57.8 to 66.0)52.4 (46.3 to 58.5)
Statistical analysis
  • Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy · Difference in percentage: 9.8 · 95% CI 2.7 to 16.9Based on Miettinen \& Nurminen method stratified by nodal status (positive vs. negative), tumor size (T1/T2 vs. T3/T4) and choice of carboplatin (Q3W vs. Weekly).
SecondarypCR Rate Using the Definition of ypT0/Tis ypN0 (i.e., no Invasive Residual in Breast or Nodes; Noninvasive Breast Residuals Allowed) at the Time of Definitive Surgery in Participants With PD-L1 Positive Tumors (CPS ≥ 1)

pCR rate (ypT0/Tis ypN0) was defined as the percentage of participants without residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy by current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery.

Time frame:
Up to approximately 27-30 weeks
Reported as:
Number · Percentage of Participants
pCR Rate Using the Definition of ypT0/Tis ypN0 (i.e., no Invasive Residual in Breast or Nodes; Noninvasive Breast Residuals Allowed) at the Time of Definitive Surgery in Participants With PD-L1 Positive Tumors (CPS ≥ 1)
Percentage of ParticipantsPembrolizumab + ChemotherapyPlacebo + Chemotherapy
pCR Rate Using the Definition of ypT0/Tis ypN0 (i.e., no Invasive Residual in Breast or Nodes; Noninvasive Breast Residuals Allowed) at the Time of Definitive Surgery in Participants With PD-L1 Positive Tumors (CPS ≥ 1)67.1 (63.1 to 71.0)58.3 (52.2 to 64.2)
Statistical analysis
  • Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy · Difference in percentage: 9.0 · 95% CI 2.1 to 16.0Based on Miettinen \& Nurminen method stratified by nodal status (positive vs. negative), tumor size (T1/T2 vs. T3/T4) and choice of carboplatin (Q3W vs. Weekly).
SecondaryEFS in Participants With PD-L1 Positive Tumors (CPS ≥ 1)

EFS was defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes definitive surgery, local or distant recurrence, second primary malignancy, as assessed by Investigator, or death due to any cause.

Time frame:
Up to approximately 102 months
Reported as:
Median · Months
EFS in Participants With PD-L1 Positive Tumors (CPS ≥ 1)
MonthsPembrolizumab + ChemotherapyPlacebo + Chemotherapy
EFS in Participants With PD-L1 Positive Tumors (CPS ≥ 1)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy · Hazard ratio (hr): 0.70 · 95% CI 0.54 to 0.91Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by nodal status (positive vs. negative),tumor size (T1/T2 vs. T3/T4) and choice of carboplatin (Q3W vs. Weekly).
SecondarypCR Rate Using an Alternative Definition, ypT0/Tis (i.e., Absence of Invasive Cancer in the Breast Irrespective of Ductal Carcinoma in Situ or Nodal Involvement) at the Time of Definitive Surgery in All Participants

pCR rate (ypT0/Tis) was defined as the percentage of participants without invasive cancer in the breast irrespective of ductal carcinoma in situ or nodal involvement following completion of neoadjuvant systemic therapy by current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery.

Time frame:
Up to approximately 27-30 weeks
Reported as:
Number · Percentage of Participants
pCR Rate Using an Alternative Definition, ypT0/Tis (i.e., Absence of Invasive Cancer in the Breast Irrespective of Ductal Carcinoma in Situ or Nodal Involvement) at the Time of Definitive Surgery in All Participants
Percentage of ParticipantsPembrolizumab + ChemotherapyPlacebo + Chemotherapy
pCR Rate Using an Alternative Definition, ypT0/Tis (i.e., Absence of Invasive Cancer in the Breast Irrespective of Ductal Carcinoma in Situ or Nodal Involvement) at the Time of Definitive Surgery in All Participants66.8 (63.1 to 70.4)57.4 (51.8 to 62.7)
Statistical analysis
  • Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy · Difference in percentage: 9.3 · 95% CI 3.1 to 15.7Based on Miettinen \& Nurminen method stratified by nodal status (positive vs. negative), tumor size (T1/T2 vs. T3/T4) and choice of carboplatin (Q3W vs. Weekly).
SecondarypCR Rate Using an Alternative Definition, ypT0/Tis (i.e., Absence of Invasive Cancer in the Breast Irrespective of Ductal Carcinoma in Situ or Nodal Involvement) at the Time of Definitive Surgery in Participants With PD-L1 Positive Tumors (CPS ≥ 1)

pCR rate (ypT0/Tis) was defined as the percentage of participants without invasive cancer in the breast irrespective of ductal carcinoma in situ or nodal involvement following completion of neoadjuvant systemic therapy by current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery.

Time frame:
Up to approximately 27-30 weeks
Reported as:
Number · Percentage of Participants
pCR Rate Using an Alternative Definition, ypT0/Tis (i.e., Absence of Invasive Cancer in the Breast Irrespective of Ductal Carcinoma in Situ or Nodal Involvement) at the Time of Definitive Surgery in Participants With PD-L1 Positive Tumors (CPS ≥ 1)
Percentage of ParticipantsPembrolizumab + ChemotherapyPlacebo + Chemotherapy
pCR Rate Using an Alternative Definition, ypT0/Tis (i.e., Absence of Invasive Cancer in the Breast Irrespective of Ductal Carcinoma in Situ or Nodal Involvement) at the Time of Definitive Surgery in Participants With PD-L1 Positive Tumors (CPS ≥ 1)70.0 (66.0 to 73.8)61.3 (55.2 to 67.1)
Statistical analysis
  • Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy · Difference in percentage: 8.8 · 95% CI 2.1 to 15.7Based on Miettinen \& Nurminen method stratified by nodal status (positive vs. negative), tumor size (T1/T2 vs. T3/T4) and choice of carboplatin (Q3W vs. Weekly)
SecondaryOverall Survival (OS) in Participants With PD-L1 Positive Tumors (CPS ≥ 1)

OS was defined as the time from randomization to death due to any cause.

Time frame:
Up to approximately 102 months
Reported as:
Median · Months
Overall Survival (OS) in Participants With PD-L1 Positive Tumors (CPS ≥ 1)
MonthsPembrolizumab + ChemotherapyPlacebo + Chemotherapy
Overall Survival (OS) in Participants With PD-L1 Positive Tumors (CPS ≥ 1)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy · Hazard ratio (hr): 0.69 · 95% CI 0.51 to 0.95Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by nodal status (positive vs. negative),tumor size (T1/T2 vs. T3/T4) and choice of carboplatin (Q3W vs. Weekly).
SecondaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE was any untoward medical occurrence in a participant administered a pharmaceutical product which does not have to have a causal relationship with this treatment. An AE can be any unfavorable and unintended sign (including abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the product or procedure. Any worsening (any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the Sponsor's product was an AE. The number of participants who experienced an AE was reported. AEs were reported for the neoadjuvant phase, adjuvant phase, and combined phases. Each participant is counted a single time for each applicable adverse event per treatment phase (i.e. Neoadjuvant, Adjuvant, Combined).

Time frame:
Up to approximately 107 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsPembrolizumab + Chemotherapy (Neoadjuvant Phase)Placebo + Chemotherapy (Neoadjuvant Phase)Pembrolizumab (Adjuvant Phase)Placebo (Adjuvant Phase)Pembrolizumab + Chemotherapy / Pembrolizumab (Neoadjuvant and Adjuvant Combined Phases)Placebo + Chemotherapy / Placebo (Neoadjuvant and Adjuvant Combined Phases)
Number of Participants Who Experienced an Adverse Event (AE)777389541294777389
SecondaryNumber of Participants Who Discontinued Study Treatment Due to an AE

An AE was any untoward medical occurrence in a participant administered a pharmaceutical product which does not have to have a causal relationship with this treatment. An AE can be any unfavorable and unintended sign (including abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the product or procedure. Any worsening (clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the Sponsor's product was an AE. The number of participants who discontinued study treatment due to an AE was reported for the neoadjuvant phase, adjuvant phase, and combined phases. Each participant is counted a single time for each applicable event per treatment phase (i.e. Neoadjuvant, Adjuvant, Combined).

Time frame:
Up to approximately 95 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Treatment Due to an AE
ParticipantsPembrolizumab + Chemotherapy (Neoadjuvant Phase)Placebo + Chemotherapy (Neoadjuvant Phase)Pembrolizumab (Adjuvant Phase)Placebo (Adjuvant Phase)Pembrolizumab + Chemotherapy / Pembrolizumab (Neoadjuvant and Adjuvant Combined Phases)Placebo + Chemotherapy / Placebo (Neoadjuvant and Adjuvant Combined Phases)
Number of Participants Who Discontinued Study Treatment Due to an AE2045332823360
SecondaryChange From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score in All Participants

The EORTC QLQ-C30 assesses quality of life in cancer patients and includes 30 questions: 1 global scale; 5 functional scales (physical, role, cognitive, emotional, social); 3 symptom scales (fatigue, nausea, pain); 6 symptoms (dyspnea, appetite loss, insomnia, constipation, diarrhea); \& financial impact. Items are scored on a 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scale scores are standardized to 0-100. Higher global and functional scores indicate better functioning, while higher symptom scores indicate worse symptoms. Results were presented separately for the neoadjuvant and adjuvant phases, with side-by-side review of phase-specific outputs. A combined phase analysis was not presented because the phases represent distinct clinical settings with different baselines; the adjuvant population is a subset of the neoadjuvant population; and pooling data would introduce substantial missingness, limiting clinical interpretability of the results.

Time frame:
Neoadjuvant: Baseline and Week 21; Adjuvant: Baseline and Week 24
Reported as:
Least squares mean · Score on a scale
Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score in All Participants
Score on a scalePembrolizumab + Chemotherapy (Neoadjuvant Phase)Placebo + Chemotherapy (Neoadjuvant Phase)Pembrolizumab (Adjuvant Phase)Placebo (Adjuvant Phase)
Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score in All Participants-11.24 (-12.82 to -9.66)-10.20 (-12.30 to -8.10)2.47 (1.05 to 3.88)2.88 (1.05 to 4.71)
SecondaryChange From Baseline in EORTC QLQ-C30 Score in Participants With PD-L1 Positive Tumors (CPS ≥ 1)

The EORTC QLQ-C30 assesses quality of life in cancer patients and includes 30 questions: 1 global scale; 5 functional scales (physical, role, cognitive, emotional, social); 3 symptom scales (fatigue, nausea, pain); 6 symptoms (dyspnea, appetite loss, insomnia, constipation, diarrhea); \& financial impact. Items are scored on a 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scale scores are standardized to 0-100. Higher global and functional scores indicate better functioning, while higher symptom scores indicate worse symptoms. Results were presented separately for the neoadjuvant and adjuvant phases, with side-by-side review of phase-specific outputs. A combined phase analysis was not presented because the phases represent distinct clinical settings with different baselines; the adjuvant population is a subset of the neoadjuvant population; and pooling data would introduce substantial missingness, limiting clinical interpretability of the results.

Time frame:
Neoadjuvant: Baseline and Week 21; Adjuvant: Baseline and Week 24
Reported as:
Least squares mean · Score on a scale
Change From Baseline in EORTC QLQ-C30 Score in Participants With PD-L1 Positive Tumors (CPS ≥ 1)
Score on a scalePembrolizumab + Chemotherapy (Neoadjuvant Phase)Placebo + Chemotherapy (Neoadjuvant Phase)Pembrolizumab (Adjuvant Phase)Placebo (Adjuvant Phase)
Change From Baseline in EORTC QLQ-C30 Score in Participants With PD-L1 Positive Tumors (CPS ≥ 1)-11.63 (-13.35 to -9.91)-10.95 (-13.25 to -8.64)1.88 (0.31 to 3.46)2.49 (0.47 to 4.51)
SecondaryChange From Baseline in EORTC Breast Cancer-Specific Quality of Life Questionnaire (QLQ-BR23) Breast Symptoms Score in All Participants

The EORTC QLQ-BR23 is a breast-specific module of the EORTC QLQ. It includes 23 items composed of 4 functional scales (body image, sexual functioning, sexual enjoyment, future perspective) and 4 symptom scales (systemic therapy side effects, breast symptoms, arm symptoms and upset by hair loss). Individual responses are given on a 4-point scale (1=Not at All to 4=Very Much). Scores for each scale are standardized into a range of 0 to 100. A higher score on the symptom scale shows a higher ("worse") level of symptoms. Results were presented separately for the neoadjuvant and adjuvant phases, with side-by-side review of phase-specific outputs. A combined phase analysis was not presented because the phases represent distinct clinical settings with different baselines; the adjuvant population is a subset of the neoadjuvant population; and pooling data would introduce substantial missingness, limiting clinical interpretability of the results.

Time frame:
Neoadjuvant: Baseline and Week 21; Adjuvant: Baseline and Week 24
Reported as:
Least squares mean · Score on a scale
Change From Baseline in EORTC Breast Cancer-Specific Quality of Life Questionnaire (QLQ-BR23) Breast Symptoms Score in All Participants
Score on a scalePembrolizumab + Chemotherapy (Neoadjuvant Phase)Placebo + Chemotherapy (Neoadjuvant Phase)Pembrolizumab (Adjuvant Phase)Placebo (Adjuvant Phase)
Change From Baseline in EORTC Breast Cancer-Specific Quality of Life Questionnaire (QLQ-BR23) Breast Symptoms Score in All Participants-9.92 (-11.34 to -8.49)-9.78 (-11.53 to -8.03)-5.73 (-7.32 to -4.15)-6.02 (-8.04 to -4.01)
PrimaryPathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0 (i.e., no Invasive Residual in Breast or Nodes; Noninvasive Breast Residuals Allowed) as Assessed at the Time of Definitive Surgery in All Participants

pCR rate (ypT0/Tis ypN0) was defined as the percentage of participants without residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy by current American Joint Committee on Cancer (AJCC) staging criteria assessed by the local pathologist at the time of definitive surgery.

Time frame:
Up to approximately 27-30 weeks
Reported as:
Number · Percentage of Participants
Pathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0 (i.e., no Invasive Residual in Breast or Nodes; Noninvasive Breast Residuals Allowed) as Assessed at the Time of Definitive Surgery in All Participants
Percentage of ParticipantsPembrolizumab + ChemotherapyPlacebo + Chemotherapy
Pathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0 (i.e., no Invasive Residual in Breast or Nodes; Noninvasive Breast Residuals Allowed) as Assessed at the Time of Definitive Surgery in All Participants64.0 (60.2 to 67.6)54.7 (49.1 to 60.1)
Statistical analysis
  • Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy · Stratified Miettinen & Nurminen · p = 0.00221 (One-sided p-value.) · Difference in percentage: 9.2 · 95% CI 2.8 to 15.6Based on Miettinen \& Nurminen method stratified by nodal status (positive vs. negative), tumor size (T1/T2 vs. T3/T4) and choice of carboplatin (Q3W vs. Weekly).
PrimaryEvent-free Survival (EFS) in All Participants

EFS was defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes definitive surgery, local or distant recurrence, second primary malignancy, as assessed by Investigator, or death due to any cause.

Time frame:
Up to approximately 102 months
Reported as:
Median · Months
Event-free Survival (EFS) in All Participants
MonthsPembrolizumab + ChemotherapyPlacebo + Chemotherapy
Event-free Survival (EFS) in All ParticipantsNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy · Log Rank · p = .0005943 (One-sided p-value based on log-rank test stratified by nodal status (positive vs negative), tumor size (T1/T2 vs T3/T4) and choice of carboplatin (Q3W vs Weekly).) · Hazard ratio (hr): 0.68 · 95% CI 0.54 to 0.86Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by nodal status (positive vs. negative), tumor size (T1/T2 vs. T3/T4) and choice of carboplatin (Q3W vs. Weekly).
SecondaryChange From Baseline in EORTC QLQ-BR23 Breast Symptoms Score in Participants With PD-L1 Positive Tumors (CPS ≥ 1)

The EORTC QLQ-BR23 is a breast-specific module of the EORTC QLQ. It includes 23 items composed of 4 functional scales (body image, sexual functioning, sexual enjoyment, future perspective) and 4 symptom scales (systemic therapy side effects, breast symptoms, arm symptoms and upset by hair loss). Individual responses are given on a 4-point scale (1=Not at All to 4=Very Much). Scores for each scale are standardized into a range of 0 to 100. A higher score on the symptom scale shows a higher ("worse") level of symptoms. Results were presented separately for the neoadjuvant and adjuvant phases, with side-by-side review of phase-specific outputs. A combined phase analysis was not presented because the phases represent distinct clinical settings with different baselines; the adjuvant population is a subset of the neoadjuvant population; and pooling data would introduce substantial missingness, limiting clinical interpretability of the results.

Time frame:
Neoadjuvant: Baseline and Week 21; Adjuvant: Baseline and Week 24
Reported as:
Least squares mean · Score on a scale
Change From Baseline in EORTC QLQ-BR23 Breast Symptoms Score in Participants With PD-L1 Positive Tumors (CPS ≥ 1)
Score on a scalePembrolizumab + Chemotherapy (Neoadjuvant Phase)Placebo + Chemotherapy (Neoadjuvant Phase)Pembrolizumab (Adjuvant Phase)Placebo (Adjuvant Phase)
Change From Baseline in EORTC QLQ-BR23 Breast Symptoms Score in Participants With PD-L1 Positive Tumors (CPS ≥ 1)-9.43 (-11.03 to -7.84)-9.19 (-11.17 to -7.21)-5.47 (-7.26 to -3.67)-6.27 (-8.53 to -4.00)

Adverse events

Collected over Up to approximately 102 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pembrolizumab + Chemotherapy (Neoadjuvant Phase)9/783 (1.1%)315/783 (40.2%)774/783 (98.9%)
Placebo + Chemotherapy (Neoadjuvant Phase)2/389 (0.5%)101/389 (26%)389/389 (100%)
Pembrolizumab (Adjuvant Phase)7/588 (1.2%)41/588 (7%)482/588 (82%)
Placebo (Adjuvant Phase)6/331 (1.8%)14/331 (4.2%)268/331 (81%)
Pembrolizumab + Chemotherapy / Pembrolizumab (Neoadjuvant and Adjuvant Combined Phases)120/784 (15.3%)341/783 (43.6%)774/783 (98.9%)
Placebo + Chemotherapy / Placebo (Neoadjuvant and Adjuvant Combined Phases)90/390 (23.1%)111/389 (28.5%)389/389 (100%)
Most frequent serious events
Showing 10 of 239
Most frequent serious events
EventPembrolizumab + Chemotherapy (Neoadjuvant Phase)Placebo + Chemotherapy (Neoadjuvant Phase)Pembrolizumab (Adjuvant Phase)Placebo (Adjuvant Phase)Pembrolizumab + Chemotherapy / Pembrolizumab (Neoadjuvant and Adjuvant Combined Phases)Placebo + Chemotherapy / Placebo (Neoadjuvant and Adjuvant Combined Phases)
Febrile neutropeniaBlood and lymphatic system disorders119/78347/3890/5880/331119/78347/389
PyrexiaGeneral disorders29/7832/3890/5880/33129/7832/389
AnaemiaBlood and lymphatic system disorders20/7839/3890/5880/33120/7839/389
PneumoniaInfections and infestations4/7836/3893/5882/3317/7838/389
NeutropeniaBlood and lymphatic system disorders12/7831/3890/5880/33112/7831/389
Pulmonary embolismRespiratory, thoracic and mediastinal disorders10/7832/3892/5880/33112/7832/389
PancytopeniaBlood and lymphatic system disorders11/7834/3890/5880/33111/7834/389
Postoperative wound infectionInfections and infestations3/7834/3890/5881/3313/7835/389
SepsisInfections and infestations7/7834/3892/5880/3319/7834/389
PneumonitisRespiratory, thoracic and mediastinal disorders5/7833/3894/5881/3319/7834/389
Most frequent other events
Showing 10 of 71
Most frequent other events
EventPembrolizumab + Chemotherapy (Neoadjuvant Phase)Placebo + Chemotherapy (Neoadjuvant Phase)Pembrolizumab (Adjuvant Phase)Placebo (Adjuvant Phase)Pembrolizumab + Chemotherapy / Pembrolizumab (Neoadjuvant and Adjuvant Combined Phases)Placebo + Chemotherapy / Placebo (Neoadjuvant and Adjuvant Combined Phases)
NauseaGastrointestinal disorders512/783254/38940/58826/331522/783256/389
AlopeciaSkin and subcutaneous tissue disorders476/783226/3894/5880/331477/783226/389
AnaemiaBlood and lymphatic system disorders448/783222/38934/58816/331452/783223/389
NeutropeniaBlood and lymphatic system disorders370/783186/38938/58826/331371/783189/389
FatigueGeneral disorders346/783156/38950/58831/331366/783168/389
ConstipationGastrointestinal disorders323/783137/38932/58819/331328/783150/389
DiarrhoeaGastrointestinal disorders293/783119/38952/58829/331316/783133/389
ArthralgiaMusculoskeletal and connective tissue disorders137/78375/389110/58866/331228/783122/389
VomitingGastrointestinal disorders233/783104/38927/5889/331243/783107/389
Alanine aminotransferase increasedInvestigations228/783104/38931/58815/331236/783108/389

Baseline characteristics

The baseline analysis population consisted of all randomized participants.

Age, Continuous
Age, Continuous(Years)Pembrolizumab + ChemotherapyPlacebo + ChemotherapyTotal
Mean49.2 ± 11.849.1 ± 11.949.1 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Pembrolizumab + ChemotherapyPlacebo + ChemotherapyTotal
Female7833901173
Male101
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pembrolizumab + ChemotherapyPlacebo + ChemotherapyTotal
Hispanic or Latino8539124
Not Hispanic or Latino616307923
Unknown or Not Reported8344127
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pembrolizumab + ChemotherapyPlacebo + ChemotherapyTotal
American Indian or Alaska Native14721
Asian14989238
Native Hawaiian or Other Pacific Islander101
Black or African American381553
White504242746
More than one race13619
Unknown or Not Reported653196
Nodal Status
Nodal Status(Participants)Pembrolizumab + ChemotherapyPlacebo + ChemotherapyTotal
Positive405200605
Negative379190569
Tumor Size
Tumor Size(Participants)Pembrolizumab + ChemotherapyPlacebo + ChemotherapyTotal
T1/T2580290870
T3/T4204100304
Choice of Carboplatin
Choice of Carboplatin(Participants)Pembrolizumab + ChemotherapyPlacebo + ChemotherapyTotal
Every 3 Weeks (Q3W)335167502
Weekly449223672
08

Study locations

193 sites
  • Virginia G. Piper Cancer Center Pharmacy - Scottsdale Healthcare ( Site 0089)
    Scottsdale, Arizona 85268, United States
  • Arizona Oncology Associates PC- HOPE ( Site 8001)
    Tucson, Arizona 85711, United States
  • Cedars Sinai Medical Center ( Site 0091)
    Los Angeles, California 90048, United States
  • Pacific Cancer Care ( Site 0069)
    Monterey, California 93940, United States
  • ICRI ( Site 0072)
    Whittier, California 90603, United States
  • University of Colorado Cancer Center ( Site 0021)
    Aurora, Colorado 80045, United States
  • Yale University School of Medicine ( Site 0054)
    New Haven, Connecticut 06510, United States
  • Christiana Hospital ( Site 0029)
    Newark, Delaware 19713, United States
  • Univ of Miami-Sylvester Comprehensive Cancer Center- Kendall satellite ( Site 0079)
    Miami, Florida 33176, United States
  • The University of Chicago Medical Center ( Site 0047)
    Chicago, Illinois 60637-1447, United States
  • North Shore University Health System ( Site 0081)
    Evanston, Illinois 60201, United States
  • Orchard Healthcare Research Inc. ( Site 0049)
    Skokie, Illinois 60077, United States
  • Goshen Center for Cancer Care ( Site 0010)
    Goshen, Indiana 46526, United States
  • University of Iowa Hospital and Clinics ( Site 0038)
    Iowa City, Iowa 52242, United States
  • New England Cancer Specialists ( Site 0005)
    Scarborough, Maine 04074, United States
  • Henry Ford Hospital ( Site 0003)
    Detroit, Michigan 48202, United States
  • Minnesota Oncology Hematology, PA ( Site 8013)
    Minneapolis, Minnesota 55404, United States
  • Rutgers Cancer Institute of New Jersey ( Site 0073)
    New Brunswick, New Jersey 08903, United States
  • Broome Oncology, LLC ( Site 8002)
    Johnson City, New York 13790, United States
  • Nyack Hospital Infusion Center ( Site 0059)
    Nyack, New York 10960, United States
  • TriHealth Cancer Institute-Good Samaritan Hospital ( Site 0044)
    Cincinnati, Ohio 45220, United States
  • Oncology Hematology Care, Inc. ( Site 8011)
    Cincinnati, Ohio 45242, United States
  • Providence Portland Medical Center ( Site 0052)
    Portland, Oregon 97213, United States
  • Northwest Cancer Specialists, P.C. ( Site 8008)
    Portland, Oregon 97227, United States
  • Magee - Women's Hospital ( Site 0011)
    Pittsburgh, Pennsylvania 15213, United States
  • Rhode Island Hospital ( Site 0060)
    Providence, Rhode Island 02903, United States
  • The West Clinic, P.C. ( Site 0078)
    Germantown, Tennessee 38138, United States
  • Texas Oncology-Austin Central ( Site 8005)
    Austin, Texas 78731, United States
  • Parkland Health and Hospital System ( Site 0093)
    Dallas, Texas 75235, United States
  • Texas Oncology-Baylor Charles A. Sammons Cancer Center ( Site 8006)
    Dallas, Texas 75246, United States
  • Simmons Cancer Center ( Site 0094)
    Dallas, Texas 75390-9015, United States
  • UT Southwestern Medical Center ( Site 0030)
    Dallas, Texas 75390-9179, United States
  • Moncrief Cancer Institute ( Site 0092)
    Fort Worth, Texas 76104, United States
  • Texas Oncology-Memorial City ( Site 8003)
    Houston, Texas 77024, United States
  • Houston Methodist Cancer Center ( Site 0013)
    Houston, Texas 77030, United States
  • Texas Oncology- Plano East ( Site 8010)
    Plano, Texas 75075, United States
  • Texas Oncology-San Antonio Northeast ( Site 8012)
    San Antonio, Texas 78217, United States
  • Texas Oncology-Tyler ( Site 8007)
    Tyler, Texas 75702, United States
  • University of Virginia ( Site 0022)
    Charlottesville, Virginia 22903, United States
  • Virginia Cancer Specialists, PC ( Site 8009)
    Fairfax, Virginia 22031, United States
  • Bon Secours Cancer Institute Medical Oncology at St. Mary's ( Site 0033)
    Midlothian, Virginia 23114, United States
  • Peninsula Cancer Institute, LLC ( Site 0041)
    Newport News, Virginia 23601, United States
  • Virginia Oncology Associates ( Site 8000)
    Norfolk, Virginia 23502, United States
  • Kadlec Clinic Hematology and Oncology ( Site 0087)
    Kennewick, Washington 99336, United States
  • Seattle Cancer Care Alliance ( Site 0068)
    Seattle, Washington 98109, United States
  • Medical Oncology Associates (Summit Cancer Centers) ( Site 0014)
    Spokane, Washington 99208, United States
  • YVMH dba Vrigina Mason Memorial/North Star Lodge Cancer Center ( Site 8004)
    Yakima, Washington 98902, United States
  • Royal North Shore Hospital ( Site 2000)
    Sydney, New South Wales 2065, Australia
  • Westmead Hospital ( Site 2002)
    Sydney, New South Wales 2145, Australia
  • Royal Adelaide Hospital ( Site 2008)
    Adelaide, South Australia 5000, Australia
  • Cabrini Health ( Site 2009)
    Malvern East, Victoria 3145, Australia
  • Frankston Hospital ( Site 2010)
    Franskton, 3199, Australia
  • Royal Brisbane and Women s Hospital ( Site 2003)
    Herston, 4029, Australia
  • St John of God Subiaco Hospital ( Site 2006)
    Perth, 6008, Australia
  • Hospital Nossa Senhora da Conceicao ( Site 0203)
    Porto Alegre, Rio Grande do Sul 91350-200, Brazil
  • UOPECCAN - Uniao Oeste Paranaense de Estudos e Combate ao Cancer ( Site 0206)
    Cascavel, 85806-300, Brazil
  • Universidade de Caxias do Sul ( Site 0201)
    Caxias do Sul, 95070-560, Brazil
  • Hospital Erasto Gaertner ( Site 0207)
    Curitiba, 81520-060, Brazil
  • Instituto do Cancer do Ceara ( Site 0205)
    Fortaleza, 60430-230, Brazil
  • Hospital Araujo Jorge ( Site 0204)
    Goiânia, 74605-070, Brazil
  • Hospital Sao Lucas da PUCRS ( Site 0200)
    Porto Alegre, 90610-900, Brazil
  • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto ( Site 0208)
    São José do Rio Preto, 15090-000, Brazil
  • Instituto do Cancer de Sao Paulo - ICESP ( Site 0211)
    São Paulo, 01246-000, Brazil
  • Tom Baker Cancer Centre ( Site 0105)
    Calgary, Alberta T2N 4N2, Canada
  • The Ottawa Hospital - Cancer Care ( Site 0100)
    Ottawa, Ontario K1H 8L6, Canada
  • Princess Margaret Cancer Centre ( Site 0103)
    Toronto, Ontario M5G 2M9, Canada
  • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0106)
    Montreal, Quebec H2X 0C1, Canada
  • Jewish General Hospital ( Site 0101)
    Montreal, Quebec H3T 1E2, Canada
  • CHU de Quebec Universite Laval - Hopital du Saint-Sacrement ( Site 0104)
    Québec, Quebec G1S 4L8, Canada
  • CIUSSS de l'Estrie-CHUS ( Site 0102)
    Sherbrooke, Quebec J1H 5N4, Canada
  • Oncomedica S.A. ( Site 0404)
    Montería, Departamento de Córdoba 230002, Colombia
  • Oncologos del Occidente S.A. ( Site 0405)
    Pereira, Risaralda Department 661002, Colombia
  • Hospital Universitario San Ignacio ( Site 0401)
    Bogotá, 110231, Colombia
  • Instituto Nacional de Cancerologia [Bogota-Colombia] ( Site 0403)
    Bogotá, 110411, Colombia
  • Hemato Oncologos S.A. ( Site 0400)
    Cali, 760001, Colombia
  • Instituto De Cancerologia S.A. ( Site 0406)
    Medellín, 050024, Colombia
  • CHU Jean Minjoz ( Site 0917)
    Besançon, 25000, France
  • Polyclinique Bordeaux Nord Aquitaine ( Site 0911)
    Bordeaux, 33077, France
  • Centre Francois Baclesse ( Site 0907)
    Caen, 14000, France
  • Centre Jean Perrin ( Site 0903)
    Clermont-Ferrand, 63001, France
  • Clinique Victor Hugo ( Site 0901)
    Le Mans, 72015, France
  • Hopital prive du Confluent ( Site 0902)
    Nantes, 44277, France
  • Institut Curie ( Site 0909)
    Paris, 75005, France
  • Hopital Saint Louis ( Site 0908)
    Paris, 75010, France
  • Hopital Diaconesses Croix Saint Simon ( Site 0905)
    Paris, 75020, France
  • CHU de la Miletrie Poitiers ( Site 0913)
    Poitiers, 86021, France
  • Institut Claudius Regaud IUCT Oncopole ( Site 0914)
    Toulouse, 31059, France
  • HELIOS Klinikum Berlin-Buch ( Site 1005)
    Berlin, 13125, Germany
  • Gynaekologisches Zentrum ( Site 1004)
    Bonn, 53111, Germany
  • Universitaetsklinikum Erlangen ( Site 1001)
    Erlangen, 91054, Germany
  • Kliniken Essen Mitte ( Site 1012)
    Essen, 45136, Germany
  • Universitaetsklinik und Poliklinik Halle/Saale ( Site 1008)
    Halle, 06120, Germany
  • Universitaetsklinikum Hamburg-Eppendorf ( Site 1007)
    Hamburg, 20246, Germany
  • Klinikum der Universit. Muenchen ( Site 1002)
    München, 80337, Germany
  • Caritasklinik St. Theresia ( Site 1011)
    Saarbrücken, 66113, Germany
  • Universitaets-Frauenklinik Tuebingen ( Site 1003)
    Tübingen, 72076, Germany
  • Bon Secours Hospital ( Site 1551)
    Cork, T12 DV56, Ireland
  • St Vincents University Hospital ( Site 1550)
    Dublin, D04 T6F4, Ireland
  • Assaf Harofeh MC ( Site 1605)
    Beer Yaakov-Zerifin, 7030001, Israel
  • Oncology institute ( Site 1601)
    Beersheba, 8410101, Israel

Showing the first 100 of 193 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, Kummel S, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Im SA, Untch M, Fasching PA, Mouret-Reynier MA, Foukakis T, Ferreira M, Cardoso F, Zhou X, Karantza V, Tryfonidis K, Aktan G, O'Shaughnessy J; KEYNOTE-522 Investigators. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. N Engl J Med. 2024 Nov 28;391(21):1981-1991. doi: 10.1056/NEJMoa2409932. Epub 2024 Sep 15. PubMed 39282906 ↗
  • Kuemmel S, Fasching PA, Schmid P, Harbeck N, Takahashi M, Untch M, Boileau JF, Cortes J, Dent R, O'Shaughnessy J, Pusztai L, Foukakis T, Park YH, Hui R, Cardoso F, Denkert C, Jia L, Pan W, Karantza V, McArthur H. Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study. Ann Surg Oncol. 2026 Jun;33(6):5550-5557. doi: 10.1245/s10434-026-19121-2. Epub 2026 Feb 25. PubMed 41739398 ↗
  • Takahashi M, Mukai H, Takano T, Tsugawa K, Inoue K, Itoh M, Watanabe J, Tanabe Y, Yamamoto N, Miyoshi Y, Watanabe K, Mukohara T, Kong Y, Shimura M, Beca F, Schmid P, Iwata H. Pembrolizumab for Early-Stage Triple-Negative Breast Cancer: KEYNOTE-522 Japan Subgroup Analysis. Cancer Sci. 2026 Apr;117(4):1106-1116. doi: 10.1111/cas.70307. Epub 2026 Jan 14. PubMed 41536071 ↗
  • Dent R, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Haiderali A, Jia L, Nguyen AM, Pan W, O'Shaughnessy J, Schmid P. Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study. J Natl Cancer Inst. 2024 Oct 1;116(10):1654-1663. doi: 10.1093/jnci/djae129. PubMed 38913881 ↗
  • Favre-Bulle A, Huang M, Haiderali A, Bhadhuri A. Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland. Pharmacoecon Open. 2024 Jan;8(1):91-101. doi: 10.1007/s41669-023-00445-8. Epub 2023 Nov 24. PubMed 37999854 ↗
  • Takahashi M, Cortes J, Dent R, Pusztai L, McArthur H, Kummel S, Denkert C, Park YH, Im SA, Ahn JH, Mukai H, Huang CS, Chen SC, Kim MH, Jia L, Li XT, Tryfonidis K, Karantza V, Iwata H, Schmid P. Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2023 Nov 1;6(11):e2342107. doi: 10.1001/jamanetworkopen.2023.42107. PubMed 37966841 ↗
  • Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kummel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651. PubMed 35139274 ↗
  • Perez-Garcia J, Soberino J, Racca F, Gion M, Stradella A, Cortes J. Atezolizumab in the treatment of metastatic triple-negative breast cancer. Expert Opin Biol Ther. 2020 Sep;20(9):981-989. doi: 10.1080/14712598.2020.1769063. Epub 2020 May 25. PubMed 32450725 ↗
  • Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549. PubMed 32101663 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Oct 2025, 103 months.

Results were first posted in Oct 2026, 1 year after primary completion.

Of 60 phase 3 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 103. This study's 103 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2017
First posted
Jan 30, 2017
StartActual
Mar 7, 2017
Primary completionActual
Oct 14, 2025
CompletionActual
Oct 14, 2025
Results first posted
Oct 22, 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 22, 2026
Interventions
Changed Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim→Granulocyte colony stimulating factor: Filgrastim or Pegfilgrastim
Oct 22, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedPathological complete responseComplete Response (pCR) rate usingRate Using the definitionDefinition of ypT0/Tis ypN0 (i.e., no invasive residualInvasive Residual in breastBreast or nodesNodes; noninvasive breast residuals allowedNoninvasive Breast Residuals Allowed) as Assessed at the timeTime of definitive surgeryDefinitive Surgery in All ParticipantsTime frame: Up to approximately 27-30 weeks
  • EditedEvent-free Survival (EFS) as assessed by Investigatorin All ParticipantsTime frame: Up to approximately 8 years → Up to approximately 102 months
Oct 22, 2026
Documents
Secondary outcomes
9 edited, 5 added
What changed in the outcomes
  • EditedpCR rate usingRate Using an alternative definitionAlternative Definition, ypT0 ypN0 (i.e., no invasiveInvasive or noninvasive residualNoninvasive Residual in breastBreast or nodesNodes) at the timeTime of definitive surgeryDefinitive Surgery in All ParticipantsTime frame: Up to approximately 27-30 weeks
  • EditedpCR rate using the definition ofRate Using an Alternative Definition, ypT0/Tis ypN0 (i.e., no invasive residualInvasive or Noninvasive Residual in breastBreast or nodes; noninvasive breast residuals allowedNodes) at the timeTime of definitive surgeryDefinitive Surgery in Participants With Programmed Death Ligand 1 (PD-L1) Positive Tumors (Combined Positive Score [CPS] ≥ 1)Time frame: Up to approximately 27-30 weeks
  • EditedEFS in participants with tumors expressingParticipants With PD-L1 Positive Tumors (CPS ≥ 1)Time frame: Up to approximately 8 years → Up to approximately 102 months
  • EditedpCR rate using an alternative definition,Rate Using the Definition of ypT0/Tis ypN0 (i.e., absence of invasive cancerno Invasive Residual in the breast irrespective of ductal carcinoma in situBreast or nodal involvementNodes; Noninvasive Breast Residuals Allowed) at the timeTime of definitive surgeryDefinitive Surgery in Participants With PD-L1 Positive Tumors (CPS ≥ 1)Time frame: Up to approximately 27-30 weeks
  • EditedOverall survivalSurvival (OS) in All ParticipantsTime frame: Up to approximately 8 years → Up to approximately 102 months
  • EditedPercentageNumber of participants who experienceParticipants Who Experienced an adverse eventAdverse Event (AE)Time frame: Up to approximately 61 weeks → Up to approximately 107 weeks
  • EditedPercentageNumber of participants who discontinue study treatment dueParticipants Who Discontinued Study Treatment Due to an AETime frame: Up to approximately 57 weeks → Up to approximately 95 weeks
  • EditedChange From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 Questionnaire (QLQ-C30) scoreScore in All ParticipantsTime frame: Up to approximately 27-30 weeks → Neoadjuvant: Baseline and Week 21; Adjuvant: Baseline and Week 24
  • EditedChange From Baseline in EORTC Breast Cancer-Specific QoLQuality of Life Questionnaire (QLQ-BR23) scoreBreast Symptoms Score in All ParticipantsTime frame: Up to approximately 27-30 weeks → Neoadjuvant: Baseline and Week 21; Adjuvant: Baseline and Week 24
  • AddedpCR Rate Using an Alternative Definition, ypT0/Tis (i.e., Absence of Invasive Cancer in the Breast Irrespective of Ductal Carcinoma in Situ or Nodal Involvement) at the Time of Definitive Surgery in All ParticipantsTime frame: Up to approximately 27-30 weeks
  • AddedpCR Rate Using an Alternative Definition, ypT0/Tis (i.e., Absence of Invasive Cancer in the Breast Irrespective of Ductal Carcinoma in Situ or Nodal Involvement) at the Time of Definitive Surgery in Participants With PD-L1 Positive Tumors (CPS ≥ 1)Time frame: Up to approximately 27-30 weeks
  • AddedOverall Survival (OS) in Participants With PD-L1 Positive Tumors (CPS ≥ 1)Time frame: Up to approximately 102 months
  • AddedChange From Baseline in EORTC QLQ-C30 Score in Participants With PD-L1 Positive Tumors (CPS ≥ 1)Time frame: Neoadjuvant: Baseline and Week 21; Adjuvant: Baseline and Week 24
  • AddedChange From Baseline in EORTC QLQ-BR23 Breast Symptoms Score in Participants With PD-L1 Positive Tumors (CPS ≥ 1)Time frame: Neoadjuvant: Baseline and Week 21; Adjuvant: Baseline and Week 24
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Results posted
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedPathological complete responseComplete Response (pCR) rate usingRate Using the definitionDefinition of ypT0/Tis ypN0 (i.e., no invasive residualInvasive Residual in breastBreast or nodesNodes; noninvasive breast residuals allowedNoninvasive Breast Residuals Allowed) as Assessed at the timeTime of definitive surgeryDefinitive Surgery in All ParticipantsTime frame: Up to approximately 27-30 weeks
    • EditedEvent-free Survival (EFS) as assessed by Investigatorin All ParticipantsTime frame: Up to approximately 8 years → Up to approximately 102 months
    Secondary outcomes 9 edited, 5 added
    What changed in the outcomes
    • EditedpCR rate usingRate Using an alternative definitionAlternative Definition, ypT0 ypN0 (i.e., no invasiveInvasive or noninvasive residualNoninvasive Residual in breastBreast or nodesNodes) at the timeTime of definitive surgeryDefinitive Surgery in All ParticipantsTime frame: Up to approximately 27-30 weeks
    • EditedpCR rate using the definition ofRate Using an Alternative Definition, ypT0/Tis ypN0 (i.e., no invasive residualInvasive or Noninvasive Residual in breastBreast or nodes; noninvasive breast residuals allowedNodes) at the timeTime of definitive surgeryDefinitive Surgery in Participants With Programmed Death Ligand 1 (PD-L1) Positive Tumors (Combined Positive Score [CPS] ≥ 1)Time frame: Up to approximately 27-30 weeks
    • EditedEFS in participants with tumors expressingParticipants With PD-L1 Positive Tumors (CPS ≥ 1)Time frame: Up to approximately 8 years → Up to approximately 102 months
    • EditedpCR rate using an alternative definition,Rate Using the Definition of ypT0/Tis ypN0 (i.e., absence of invasive cancerno Invasive Residual in the breast irrespective of ductal carcinoma in situBreast or nodal involvementNodes; Noninvasive Breast Residuals Allowed) at the timeTime of definitive surgeryDefinitive Surgery in Participants With PD-L1 Positive Tumors (CPS ≥ 1)Time frame: Up to approximately 27-30 weeks
    • EditedOverall survivalSurvival (OS) in All ParticipantsTime frame: Up to approximately 8 years → Up to approximately 102 months
    • EditedPercentageNumber of participants who experienceParticipants Who Experienced an adverse eventAdverse Event (AE)Time frame: Up to approximately 61 weeks → Up to approximately 107 weeks
    • EditedPercentageNumber of participants who discontinue study treatment dueParticipants Who Discontinued Study Treatment Due to an AETime frame: Up to approximately 57 weeks → Up to approximately 95 weeks
    • EditedChange From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 Questionnaire (QLQ-C30) scoreScore in All ParticipantsTime frame: Up to approximately 27-30 weeks → Neoadjuvant: Baseline and Week 21; Adjuvant: Baseline and Week 24
    • EditedChange From Baseline in EORTC Breast Cancer-Specific QoLQuality of Life Questionnaire (QLQ-BR23) scoreBreast Symptoms Score in All ParticipantsTime frame: Up to approximately 27-30 weeks → Neoadjuvant: Baseline and Week 21; Adjuvant: Baseline and Week 24
    • AddedpCR Rate Using an Alternative Definition, ypT0/Tis (i.e., Absence of Invasive Cancer in the Breast Irrespective of Ductal Carcinoma in Situ or Nodal Involvement) at the Time of Definitive Surgery in All ParticipantsTime frame: Up to approximately 27-30 weeks
    • AddedpCR Rate Using an Alternative Definition, ypT0/Tis (i.e., Absence of Invasive Cancer in the Breast Irrespective of Ductal Carcinoma in Situ or Nodal Involvement) at the Time of Definitive Surgery in Participants With PD-L1 Positive Tumors (CPS ≥ 1)Time frame: Up to approximately 27-30 weeks
    • AddedOverall Survival (OS) in Participants With PD-L1 Positive Tumors (CPS ≥ 1)Time frame: Up to approximately 102 months
    • AddedChange From Baseline in EORTC QLQ-C30 Score in Participants With PD-L1 Positive Tumors (CPS ≥ 1)Time frame: Neoadjuvant: Baseline and Week 21; Adjuvant: Baseline and Week 24
    • AddedChange From Baseline in EORTC QLQ-BR23 Breast Symptoms Score in Participants With PD-L1 Positive Tumors (CPS ≥ 1)Time frame: Neoadjuvant: Baseline and Week 21; Adjuvant: Baseline and Week 24
    Interventions Changed Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim→Granulocyte colony stimulating factor: Filgrastim or Pegfilgrastim
    + 5 other changes: index terms, identifiers, verification date, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03036488
Responsible party
Sponsor
First posted
Jan 30, 2017
Start date
Mar 7, 2017
Primary completion
Oct 14, 2025
Completion
Oct 14, 2025
Results posted
Oct 22, 2026
Last update
Oct 22, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion